How Orlistat Reshapes Midlife Metabolism with Tirzepatide Cycling in PCOS

How Orlistat Reshapes Midlife Metabolism with Tirzepatide Cycling in PCOS Welcome to CFP Weight Loss. I'm Russell Clark, Nurse Practitioner. Today, we're exploring How Orlistat Reshapes Midlife Metabolism with Tirzepatide Cycling in PCOS. ... Take a breath, settle in, and let's walk through this together — clearly, calmly, and based on what the evidence actually shows. ... We'll touch on Orlistat PCOS, Tirzepatide Cycling, Midlife Metabolism — especially as they apply to real people over forty. ... Introduction Midlife brings hormonal shifts that slow metabolism, particularly for women with PCOS where insulin resistance and visceral fat accumulation intensify. Orlistat, a lipase inhibitor, reduces dietary fat absorption by about 30%, creating a unique caloric deficit without systemic appetite suppression. When strategically paired with tirzepatide cycling under The Clark Protocol’s 6-week-on, 4-week-off structure, orlistat becomes a powerful adjunct for sustainable fat loss and metabolic repair. This approach addresses CICO fundamentals while improving HOMA-IR, A1C, and gut microbiome health—key concerns in PCOS. Listen at CFP Weight Loss — clinical guide with Russell Clark, FNP-C. Read more: https://blog.cfpweightloss.com/how-orlistat-affects-midlife-metabolism-pairing-with-tirzepatide-cycling-pcos-pa-tvfla9